Levels of circulating TNF‑related apoptosis‑inducing ligand in celiac disease

Celeghini,Claudio; Not,Tarcisio; Norcio,Alessia; Monasta,Lorenzo; Secchiero,Paola

doi:10.3892/etm.2014.2026

Levels of circulating TNF‑related apoptosis‑inducing ligand in celiac disease

Authors:
- Claudio Celeghini
- Tarcisio Not
- Alessia Norcio
- Lorenzo Monasta
- Paola Secchiero
View Affiliations

Affiliations: Department of Life Sciences, University of Trieste, Trieste I‑34138, Italy, Institute for Maternal and Child Health ‑ IRCCS ‘Burlo Garofolo’, Trieste I-34137, Italy, Department of Morphology, Surgery and Experimental Medicine and LTTA Centre, University of Ferrara, Ferrara I-44121, Italy
Published online on: October 15, 2014 https://doi.org/10.3892/etm.2014.2026
Pages: 1906-1908

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

It has previously been demonstrated that the circulating levels of TNF‑related apoptosis‑inducing ligand (TRAIL) are significantly lower in patients with type 1 diabetes (T1D) than in normal age- and gender‑matched controls. Since celiac disease (CD) is often associated with T1D, a retrospective study was performed to analyze the sera of a cohort of pediatric subjects: i) patients with CD at onset (n=100); ii) patients with potential CD (n=45); iii) patients with CD associated with other auto‑immune diseases (n=17); and iv) patients with eosinophilic esophagitis (n=15). Among the patients with CD, 49 were also analyzed after six months on a gluten‑free diet, while data were also available for 13 patients after one year on a gluten‑free diet. No significant differences were found in the circulating levels of TRAIL between the patients with CD and the patients with either eosinophilic esophagitis or potential CD. Patients with CD associated with other auto‑immune diseases showed significantly lower levels of TRAIL when compared with patients with CD alone. The gluten‑free diet did not significantly modify the levels of circulating TRAIL at 6 or 12 months. Thus, although T1D and CD share common immunological features, the circulating levels of TRAIL show a significant difference between the two pathologies, and do not appear to be modulated in CD.

View Figures

View References

1	Green PH and Cellier C: Celiac disease. N Engl J Med. 357:1731–1743. 2007. View Article : Google Scholar : PubMed/NCBI
2	Scaramuzza AE, Mantegazza C, Bosetti A and Zuccotti GV: Type 1 diabetes and celiac disease: The effects of gluten free diet on metabolic control. World J Diabetes. 4:130–134. 2013. View Article : Google Scholar : PubMed/NCBI
3	Hooft C, Roels H and Devos E: Diabetes and coeliac disease. Lancet. 2:11921969.PubMed/NCBI
4	Secchiero P and Zauli G: TNF-related apoptosis-inducing ligand and the regulation of hematopoiesis. Curr Op Hematol. 15:42–48. 2008. View Article : Google Scholar : PubMed/NCBI
5	Secchiero P, Gonelli A, Celeghini C, et al: Activation of the nitric oxide synthase pathway represents a key component of tumor necrosis factor-related apoptosis-inducing ligand-mediated cytotoxicity on hematologic malignancies. Blood. 98:2220–2228. 2001. View Article : Google Scholar
6	Vinay DS and Kwon BS: The tumour necrosis factor/TNF receptor superfamily: therapeutic targets in autoimmune diseases. Clin Exp Immunol. 164:145–157. 2011. View Article : Google Scholar : PubMed/NCBI
7	Di Bartolo BA, Chan J, Bennett MR, Cartland S, Bao S, Tuch BE and Kavurma MM: TNF-related apoptosis-inducing ligand (TRAIL) protects against diabetes and atherosclerosis in ApoE^−/− mice. Diabetologia. 54:3157–3167. 2011.PubMed/NCBI
8	Zauli G, Toffoli B, di Iasio MG, Celeghini C, Fabris B and Secchiero P: Treatment with recombinant tumor necrosis factor-related apoptosis-inducing ligand alleviates the severity of streptozotocin-induced diabetes. Diabetes. 59:1261–1265. 2010. View Article : Google Scholar
9	Tornese G, Iafusco D, Monasta L, et al: The levels of circulating TRAIL at the onset of type 1 diabetes are markedly decreased in patients with ketoacidosis and with the highest insulin requirement. Acta Diabetol. 51:239–246. 2014. View Article : Google Scholar : PubMed/NCBI
10	Zauli G, Melloni E, Capitani S and Secchiero P: Role of full-length osteoprotegerin in tumor cell biology. Cell Molecular Life Sci. 66:841–851. 2009. View Article : Google Scholar : PubMed/NCBI
11	Volpato S, Ferrucci L, Secchiero P, et al: Association of tumor necrosis factor-related apoptosis-inducing ligand with total and cardiovascular mortality in older adults. Atherosclerosis. 215:452–458. 2011. View Article : Google Scholar
12	Secchiero P, Corallini F, Ceconi C, Parrinello G, Volpato S, Ferrari R and Zauli G: Potential prognostic significance of decreased serum levels of TRAIL after acute myocardial infarction. PloS One. 4:e44422009. View Article : Google Scholar : PubMed/NCBI
13	Secchiero P, Corallini F, Beltrami AP, et al: An imbalanced OPG/TRAIL ratio is associated to severe acute myocardial infarction. Atherosclerosis. 210:274–277. 2010. View Article : Google Scholar : PubMed/NCBI
14	Xiang G, Zhang J, Ling Y and Zhao L: Circulating level of TRAIL concentration is positively associated with endothelial function and increased by diabetic therapy in the newly diagnosed type 2 diabetic patients. Clin Endocrinol (Oxf). 80:228–234. 2013. View Article : Google Scholar
15	Lahdenperä AI, Hölttä V, Ruohtula T, et al: Up-regulation of small intestinal interleukin-17 immunity in untreated coeliac disease but not in potential coeliac disease or in type 1 diabetes. Clin Exp Immunol. 167:226–234. 2012.PubMed/NCBI
16	Pagliari D, Cianci R, Frosali S, Landolfi R, Cammarota G, Newton EE and Pandolfi F: The role of IL-15 in gastrointestinal diseases: A bridge between innate and adaptive immune response. Cytokine Growth Factor Rev. 24:455–466. 2013. View Article : Google Scholar : PubMed/NCBI